1 O 2 3 4 5 6 7 8 9 UNITED STATES DISTRICT COURT 10 CENTRAL DISTRICT OF CALIFORNIA 11 Case No.: 2:20-cv-03444-MEMF-PVCx 12 SKYE ORTHOBIOLOGICS, LLC, et al.,

13 Plaintiffs, ORDER GRANTING IN PART

DEFENDANT BANMAN’S RENEWED

14 v. RULE 50 MOTION AND GRANTING IN

PART RULE 59 MOTION [ECF NOS. 540,

15 544] 16 CTM BIOMEDICAL, LLC, et al., Defendants. 17 18

19 20 21 Before the Court is a Renewed Rule 50 Motion for Judgment as a Matter of Law [ECF No. 22 540] and Rule 59 Motion for a New Trial, to Strike/Limit Damages, or for Remittitur [ECF No. 544] 23 filed by Defendant Bryan Banman. For the reasons stated herein, the Court hereby GRANTS IN 24 PART both motions. 25 26 27 / / / 28 / / / 1 BACKGROUND 2 I. Factual Background 3 Plaintiff Human Regenerative Technologies, LLC (“HRT”) processes and manufactures 4 medical products that are derived from human placental tissue. Plaintiff Skye Orthobiologics, LLC 5 (“Skye,” or collectively with HRT, the “Skye Plaintiffs” or “Plaintiffs”) sells various human tissue 6 products, including products manufactured by HRT. Defendant Bryan Banman (“Banman”) is 7 Skye’s former Senior Vice President of Business Development. Banman is also the current President 8 and CEO of Defendant CTM Biomedical, LLC (“CTM”)—a company that also sells human tissue 9 products—which he started while he was still employed by Skye. This case concerns Plaintiffs Skye 10 and HRT’s allegations that Banman—along with his new company CTM, the related entity CTM 11 Medical Inc. (“CTM Med.,” or collectively with CTM, the “CTM Defendants”), and Defendants 12 Mike Stumpe (“Stumpe”), Nathan Boulais (“Boulais”), and Pablo Seoane (“Seoane”)— 13 misappropriated the Skye Plaintiffs’ trade secrets, breached relevant contracts and duties, and 14 interfered with the Skye Plaintiffs’ contracts and prospective economic advantage. 15 II. Procedural History 16 On August 21, 2023, trial for this matter commenced before a jury. After the trial, the jury 17 made the following findings: (1) that Banman breached a Consulting Agreement/Compensation 18 Contract with HRT (Count 4), with lost profits of $7,298,949; (2) that Banman breached his April 19 18, 2018 Employment Agreement with Skye (Count 5), with lost profits of $7,298,949; (3) that 20 Banman breached his April 18, 2018 Employment Confidentiality Agreement with Skye (the “Skye 21 Confidentiality Agreement”) (Count 5), with lost profits of $7,298,949; (4) that Banman breached 22 his fiduciary duty to Skye (Count 10), with lost profits of $7,298,949 and punitive damages of 23 $12,780,000; and (5) that Banman breached his duty of loyalty to Skye (Count 11), with lost profits 24 of $7,298,949 and punitive damages of $12,780,000. ECF No. 511 (“Verdict Form”). 25 Banman previously moved under Fed. Rule Civ. Proc. 50(a) for judgment as a matter of law 26 at the conclusion of Plaintiffs’ case on August 28, 2023. ECF No. 493. The Court deferred ruling on 27 the prior motion, and directed Banman to file a renewed Rule 50 Motion as portions of the prior one 28 were mooted by the jury verdict. ECF No. 513. Accordingly, on October 16, 2023, Banman filed the 1 instant Renewed Rule 50 Motion for Judgment as a Matter of Law as well as a Rule 59 Motion for a 2 New Trial. ECF No. 540 (the “Rule 50 Motion” or “JMOL”), 544 (the “Rule 59 Motion” or 3 “MNT”). On November 13, 2023, Plaintiffs filed their oppositions. ECF No. 551 (“JMOL Opp”), 4 554 (“MNT Opp”). On November 29, 2023, Banman filed his replies. ECF No. 560 (“JMOL 5 Reply”), 564 (“MNT Reply”). The Court heard oral argument on the motions on January 10, 2024. 6 RULE 50 MOTION (JUDGMENT AS A MATTER OF LAW) [ECF NO. 540] 7 I. Applicable Law 8 A trial court can “overturn the jury and grant [a Rule 50 motion] only if, under the governing 9 law, there can be but one reasonable conclusion as to the verdict. In other words, the motion should 10 be granted only if “there is no legally sufficient basis for a reasonable jury to find for that party on 11 that issue.” Winarto v. Toshiba Am. Elecs. Components, Inc., 274 F.3d 1276, 1283 (9th Cir. 2001). 12 In considering a Rule 50 motion, “the court is not to make credibility determinations or weigh the 13 evidence and should view all inferences in the light most favorable to the nonmoving party,” 14 including accepting the jury’s credibility findings as consistent with the verdict and disregard all 15 evidence favorable to the moving party that the jury is not required to believe.” Id. 16 II. Discussion 17 Banman moves under Rule 50 for judgment as a matter of law on (1) HRT’s breach of 18 contract claim (Count 4); (2) Skye’s breach of contract claims (Count 5); (3) Skye’s breach of duty 19 claims (Counts 10 & 11); and (4) damages. For the reasons discussed below, the Court finds that the 20 jury’s findings on Counts 4, 10, and 11 are properly supported by the evidence and not contrary to 21 law. However, the Court concludes that the jury’s findings on Count 5 (as to the Skye Employee 22 Confidentiality Agreement only) are improper and grants judgment as a matter of law on this claim. 23 A. HRT’s Breach of Contract Claim is Supported (Count 4) 24 As to HRT’s breach of contract claim, the jury found that HRT entered into a Consulting 25 Agreement/Compensation Contract with Banman, that HRT performed its part of the contract, that 26 27 28 1 Banman breached the contract by using or disclosing HRT’s manufacturing process,1 including but 2 not limited to HRT’s formula for its flowable product, and that this breach was a substantial factor in 3 causing harm to HRT. Verdict Form at 12. 4 i. The jury properly found HRT’s process confidential. 5 Banman first argues that the evidence undisputedly established that HRT’s manufacturing 6 process, including its formula or ratio for its flowable product, is not confidential. JMOL at 5. 7 Banman focuses on two specific aspects of the HRT process: (1) the ratio or formula it used in its 8 flowable product (75 mg of tissue to 1 ml of saline); and (2) the maintenance of the stromal layer on 9 its chorion membrane product. Banman states that the formula is not confidential because Plaintiffs’ 10 expert, John Lee, testified that he could independently determine the ratio by separating the two 11 components, and that at least one publicly available patent application published on March 2, 2017, 12 identifies this ratio as an option for a flowable product. JMOL at 7. Similarly, Banman states that 13 Lee testified that anyone “skilled in the art” of tissue processing could hold up HRT’s chorion 14 membrane product to a light to see whether the stromal layer was intact, and that a patent application 15 published on November 22, 2012, discussed maintenance of the stromal layer. Id. 16 While these facts may, at best, show that some parts of the HRT process could possibly be 17 identified if a person sought to do so, the Court finds that there were facts sufficient to support a jury 18 finding that HRT’s manufacturing process was not public knowledge and therefore confidential. 19 Lee’s testimony was that he could reverse-engineer the specific ratio, “but the identification of the 20 parts would not be revealed, so [he] wouldn’t know how much chorion, amnion, or cord was present, 21 but [he] would know how much solid was present, which could also be desiccated saline or salt.” 22 ECF No. 540-25 at 37:18-24. Therefore, while someone an expert may be able to find out that the 23 product used 75 mg of some solid to 1 ml of some liquid, they would may not be able to specifically 24 25 26

27 1 Although the verdict form does not have a specific question relating to whether the process is confidential or not, the Court interprets that implicit in this finding is that the process is confidential as only confidential 28 1 identify what the solid or liquid was.2 Even if such information was available from other sources, a 2 jury could reasonably find that the difficulty for an average person to figure out such information 3 made it more likely than not confidential. The patent Banman points to that includes this ratio also 4 does not specifically identify the 75:1 ratio as the ideal option, and merely gives a number of 5 possibilities. ECF No. 540-15 at 11 ¶ 0077. 6 Moreover, even if the ratio could be reverse-engineered, Banman points to no authority that 7 would establish that this would preclude it from being confidential information under a contract as a 8 matter of law. Rather, in Entertainment Research Group, Inc. v. Genesis Creative Group, Inc., which 9 Banman cites to in his reply, in evaluating a breach of confidentiality claim, the Ninth Circuit’s 10 focus was not on whether a product could be reverse-engineered, but rather whether the plaintiff 11 took actions to keep the information confidential. 122 F.3d 1211, 1227–28 (9th Cir. 1997) (noting 12 that reverse-engineering is legal and therefore “by not requiring the purchasers of its costumes to 13 sign non-disclosure agreements, [the plaintiff] gave up any ability it may have had to claim that the 14 manufacturing and design information disclosed to [the defendant] was ‘confidential in nature’”).3 15 Specifically, the Ninth Circuit held that “[t]he absence of any non-disclosure agreements entered into 16 by [] previous purchasers is dispositive of the instant breach of confidence claim.” Id. (emphasis 17 added). Therefore, the emphasis is on the understanding of the parties of the confidential nature of 18 the information, rather than whether or not it would be possible for someone to independently figure 19 it out. See Tele-Count Eng’rs, Inc. v. Pac. Tel. & Tel. Co., 168 Cal. App. 3d 455, 462 (1985) (noting 20 that “by instructing the jury on appellant’s burden to establish that the confidential nature ‘of the 21 forms’ was ‘made known’ to [the defendant] by appellant, the trial court properly focused attention 22 upon the element of an understanding between the parties”). 23

24 2 Banman argues that this is irrelevant because HRT did not claim CTM used the same proportions of solids 25 in its flowable product, but what was actually used in the CTM product has no bearing on whether or not the specific information at issue is confidential. JMOL Reply at 1. 26 3 This is further supported by the definition of a trade secret, which although is not at issue here, would undoubtedly qualify as confidential information. See 18 U.S.C. § 1839(3) (defining a trade secret as 27 information the owner has taken reasonable measures to keep such information secret, and derives independent economic value from not being generally known). Therefore, in deciding whether information 28 1 Here, there was evidence from which a jury could find that the information was more likely 2 than not confidential based on Plaintiffs’ actions in keeping its manufacturing process confidential— 3 for example, evidence supported that every employee at Skye and HRT signed confidentiality 4 agreements, and there are security measures to keep the product manufacturing process confidential. 5 ECF No. 551-5 at 51:22-52:9, 72:16-74:9.4 This is sufficient for a breach of confidentiality. See 6 Faris v. Enberg, 97 Cal. App. 3d 309, 323 (1979) (“An actionable breach of confidence will arise 7 when an idea, whether or not protectable, is offered to another in confidence, and is voluntarily 8 received by the offeree in confidence with the understanding that it is not to be disclosed to others, 9 and is not to be used by the offeree for purposes beyond the limited of the confidence without the 10 offerer’s permission.”). Banman argues that it would be unfair for him to be restrained in using the 11 information beyond what any competitor would be if they were to be able to figure it out on their 12 own.5 However, as Faris makes clear, that is the point of entering into a confidentiality agreement— 13 Banman has voluntarily entered into a confidentiality agreement and therefore has obligations to 14 keep such confidentiality that others would not. Id. at 324 (distinguishing between a situation where 15 one voluntarily receives a confidential disclosure as opposed to receiving an unsolicited submission 16 of an idea). This makes sense—Plaintiffs here were likely not concerned with an expert from a niche 17 field reverse engineering its product and then starting a competing business. What Plaintiffs were 18 concerned with, and what they sought to restrain, were people that were intimately aware of their 19 manufacturing and business processes and using their work to compete with them—exactly what the 20 jury found Banman did here. 21 The same is true as to Banman’s arguments as to maintenance of the stromal layer. Lee’s 22 testimony was that not just anyone would be able to tell that it was left intact from looking at an 23

24 4 Banman also argues that the confidentiality provision must be held overbroad as a matter of law if it 25 precludes him from using information that could possibly be figured out independently. However, at issue is not what could hypothetically be done, but what Banman did in this case. As discussed further in the next 26 section, a jury could have reasonably found that Banman did not independently figure out the information. 5 At the hearing, counsel for Banman attempted to distinguish between disclosure and use, arguing that 27 restraining use would make the confidentiality provision unenforceable. ECF No. 605 at 28:1-2. The Court does not find the distinction to be significant here, as there is evidence that in the course of using such 28 1 HRT product, as only those skilled in the art of tissue processing could make such a determination. 2 ECF No. 542-5 at 40:2-5. While Banman characterizes this as a “basic observation,” Lee’s testimony 3 could be interpreted to support that this would not be easily known, since it is reasonable to assume 4 not many people are skilled in the art. JMOL Reply at 2. Even if it is possible to discern the stromal 5 layer’s presence in HRT’s product, and that other companies also maintained the stromal layer for 6 other types of products, it could still be considered confidential as part of the process to create the 7 particular product at issue. There was evidence supporting that HRT’s end product was unique, and 8 therefore the significance of keeping the stromal layer would not be obvious even if the fact of it is. 9 See ECF No. 553-5 (testimony that the product had “unique benefits and features,” and retention of 10 the stromal layer was “one of the key components of the product”). Therefore, it was appropriate for 11 the jury to weigh this evidence along with the evidence of the actions Plaintiffs took to keep their 12 manufacturing process a secret in deciding whether such information was confidential, and whether 13 it was disclosed to Banman in confidence under the contract. The jury could also appropriately 14 consider the evidence showing that Banman himself considered product formulas and specifications 15 confidential by requiring that Precision Allograft Solutions, LLC (“Alamo”), CTM’s manufacturer, 16 sign a confidentiality agreement. ECF No. 551-12. 17 Accordingly, the Court finds that Banman has not met his burden in showing that no 18 reasonable juror could have found that HRT’s manufacturing process was confidential by a 19 preponderance of the evidence, or that such a finding is contrary to the law. 20 ii. The jury properly found confidential information used or disclosed. 21 As an initial matter, part of Banman’s argument with regards to use goes towards whether 22 Banman actually knew of the ratio and the maintenance of the stromal layer by HRT. The Court 23 finds that there is evidence supporting this conclusion. ECF No. 553-4 at 17:19-23. Banman argues 24 that the evidence showed that HRT’s product at the time Banman worked on those products used a 25 different ratio. JMOL at 9. However, even if this was true, this does not undisputably refute Sharpe’s 26 testimony that Banman knew of the ratio. Sharpe testified that in an email in June of 2014, Banman 27 stated that they were “the only guys in the world who’ve created a room temp product,” referring to 28 the prior discovery they made that 75 mg “worked extremely well.” ECF No. 551-4, 553-4 at 17:19- 1 20. Therefore, it is reasonable to assume that while HRT’s product line at the time was not using this 2 specific ratio, this discovery had been made and this was part of the confidential information 3 Banman took with him to start CTM. Banman points to his own testimony as to how he 4 independently came to the ratio, but a jury could have reasonably found Banman not credible and 5 chosen to disbelieve any or all of his testimony. JMOL at 11. It is also reasonable for a jury to infer 6 that Banman knew of the significance of the maintenance of the stromal layer, as the evidence shows 7 that Banman was the one who wanted Alamo to keep the stromal layer. ECF No. 553-7 at 147:24- 8 148:01. 9 Banman also argues that there is no evidence showing that he used or disclosed any 10 confidential information with regards to HRT’s manufacturing process. Again, Banman’s argument 11 in this respect relies heavily on testimony from himself (and Lee Andrews, the CEO of Alamo), 12 whom a jury could have not found credible. For example, Banman solely relies on his and 13 Andrews’s testimony to support that he only provided “minor non-substantive contributions” to 14 Alamo’s Standard Operating Procedures (“SOP”) in manufacturing CTM’s flowable products, and 15 did not draft or edit the SOP for the flowable products specifically. JMOL at 9. But, importantly, 16 their testimony confirms that it was Banman who gave the instruction to Alamo to keep the stromal 17 layer, and use the 75:1 ratio. ECF No. 553-3 at 31:22-32:2, 32:17-21. This evidence is sufficient for 18 a jury to find use and/or disclosure of some (arguably crucial) part of HRT’s confidential process, 19 regardless of the other differences as to HRT and Alamo’s processes. 20 Accordingly, the Court finds that Banman has not met his burden in showing that no 21 reasonable juror could have found by a preponderance of the evidence that Banman used or 22 disclosed HRT’s confidential information, or that such a finding is contrary to the law. 23 iii. The HRT contract’s confidentiality provision is not void. 24 Banman argues that the confidentiality provision in his contract with HRT is facially void 25 and unenforceable as a matter of law because it precludes him from competing in an industry, and 26 using general knowledge and skill even if it was gained through his work with HRT. 27 He relies on Brown v. TGS Management Co., LLC, 57 Cal. App. 5th 303 (2020) and Dowell 28 v. Biosense Webster, Inc., 179 Cal. App. 4th 564 (2009) in support of his position and argues that the 1 HRT agreement was “substantively indistinguishable from” (JMOL Reply at 4) and “substantively 2 identical to the confidentiality provisions found invalid in Brown and Dowell.” JMOL at 13. To the 3 contrary, the provisions of the HRT agreement are significantly different from those at issue in 4 Brown and Dowell. For example, in Brown, “confidential information” was defined as “information 5 in whatever form, used or usable in, or originated, developed or acquired for use in, or about or 6 relating to the Business.” Brown, 57 Cal. App. 5th at 316 (emphasis added). “The Business” was 7 then defined to include “without limitation analyzing, executing, trading and/or heding in securities 8 and financial instruments and derivatives thereon, securities-related research, and trade processing 9 and related administration . . .” Id. This meant that confidential information was essentially defined 10 to mean all information usable in the securities industry. Id. at 317 (noting that this definition was 11 “not just statistical arbitrage—the actual business of [the company]—but, instead, refer[red] to all 12 aspects of working in the securities industries at large”). Plainly, such a definition is improper and 13 such a provision is unlawful because it seeks to prevent the signatory from using information that 14 was usable in the industry regardless of whether it was ever used by the company and regardless of 15 whether it was ever owned by the company. The provision in Dowell is even more distinguishable, 16 as there, the provision was an actual anti-compete provision. Dowell, 179 Cal. App. at 568, 575 17 (“The broadly worded noncompete clause prevents [the plaintiff], for a period of 18 months after 18 termination of employment with [the company], from rendering services, directly or indirectly, to 19 any competitor . . .”). 20 Here, the HRT agreement only prevents Banman from using HRT’s confidential information, 21 not confidential information designed as all usable information in the placental products industry. A 22 close review of the provision at issue demonstrates that. ECF No. 540-7, Section 3 (“[I]t is 23 anticipated that Consultant will have access to the Company’s proprietary or confidential 24 information . . . .”) (emphasis added). Accordingly, the confidentiality agreement plainly does not 25 prevent Banman from competing—it merely states that Banman will have access to HRT’s 26 confidential information that shall not be disclosed to any third party. The proprietary and 27 confidential information at issue is specifically limited to things “concerning the finances, business 28 and affairs of [HRT].” Id. Therefore, read literally, HRT’s provision does not, as Banman argues, 1 encompass information that is generally known in the industry or would be necessary for anyone to 2 compete in that particular field. JMOL at 13. Banman is free to start his own competing placental 3 products in the industry, and the provision only precludes him from using HRT’s confidential 4 information to do so—which is not contrary to California law. See Morlife, Inc. v. Perry, 56 Cal. 5 App. 4th 1514, 1520 (1997) (noting that “the right of free competition does not include the right to 6 use confidential work product of others”). 7 Accordingly, the Court finds that the confidentiality provision is not void as a matter of law. 8 *** 9 As the jury’s findings on HRT’s breach of contract claim are supported by the evidence and 10 not contrary to the law, the Court DENIES Banman’s Rule 50 Motion on this claim. 11 B. Skye’s Breach of Contract Claim is Not Supported (Count 5) 12 As to Skye’s breach of contract claim, the jury found that Skye entered into an Employment 13 Agreement as well as an Employee Confidentiality Agreement dated April 18, 2018 with Banman, 14 that Skye performed its part of the contract, that Banman breached the contract, and that this breach 15 was a substantial factor in causing harm to Skye. Verdict Form at 13, 14.6 Similar to the HRT 16 contract, the breach at issue was Banman’s disclosure of confidential information, including HRT’s 17 manufacturing process. This claim also included Banman’s use of Skye’s sales representative 18 training methods and order history information (excluding pricing information) with respect to Ethan 19 Chappell and Community Hospital, and Dr. Janos Ertl and Eskenazi Health. ECF No. 508 at 45. 20 As to these latter two categories, Banman argues that the jury found that Skye was not the 21 owner of its sales representative training methods or the order history information under its trade 22 secret misappropriation claim (Count 1). Verdict Form at 3, 5. The Court notes that information can 23 be confidential even if it is not a trade secret. See Tele-Count Eng’rs, Inc., 168 Cal. App. at 463. 24 Nevertheless, given that the wording of the verdict form is about the ownership of the information 25 specifically, the Court finds that the jury’s findings on Skye’s lack of ownership of this information 26 27 6 Banman’s arguments here appear directed at the Skye Employee Confidentiality Agreement only, therefore 28 1 sufficient to disregard it as the basis of liability for the breach. Therefore, the sole basis of liability 2 for Banman’s breach of contract against Skye is the same as it was for HRT—from the disclosure of 3 HRT’s confidential manufacturing process.7 And, for the same reasons as discussed above, the Court 4 finds that there is sufficient evidence to support disclosure of this information. The Court therefore 5 turns to the additional argument Banman raises with regards to the Skye Confidentiality 6 Agreement—its prospective nature. JMOL at 14. 7 The Skye Confidentiality Agreement has an exception to the “proprietary information” 8 covered under its confidentiality provision—specifically, it excludes information that Banman 9 “knew or disclosed to SKYE, its predecessors or affiliates prior to the commencement of [his] 10 employment or pursuant to the terms of the Mutual Non-Disclosure, Confidentiality & Non- 11 Circumvent Agreement dated April 23, 2012” between him and Skye. ECF No. 540-8 at 1. Banman 12 argues that everything he learned about HRT’s manufacturing process was learned prior to his 13 “employment” with Skye in April 2018, and Plaintiffs do not appear to dispute this temporal point.8 14 JMOL Opp. at 11. Rather, Plaintiffs appear to be arguing that the information was confidential 15 because it was confidential under other agreements, like HRT’s. Id. But, this is irrelevant to breach 16 of this particular contract with Skye, which is what Plaintiffs have brought their claim on. Plaintiffs 17 cannot simply piggyback off confidential information covered under one contract and extend that 18 definition to confidential information under other contracts, especially when such information is 19 expressly excluded.9 20 21 22 7 Skye makes no arguments as to the sales representative training and order history, therefore appearing to concede this point. JMOL Opp. at 10. 23 8 Plaintiffs also cite to Sharpe’s testimony that the contract was meant to cover “everything” he and Banman 24 ever worked on together, but the plain language of the contract excludes information knew prior to when he began his employment. JMOL Opp. at 11; see Wolf v. Walt Disney Pictures & Television, 162 Cal. App. 4th 25 1107, 1125 (2008) (a court “generally may not consider extrinsic evidence . . . to vary or contradict the clear and unambiguous terms of a written, integrated contract”). Plaintiffs point to no evidence that can support an 26 inference that Banman learned of the confidential information at issue in this case after April 2018. 9 Plaintiffs also inaccurately assert that the Court has affirmatively ruled on this issue before. JMOL Opp. at 27 10. The Court’s ruling on Banman’s motion in limine denied the request solely for lack of specificity as to any actual evidence sought to be excluded. ECF No. 428 at 22. Plaintiffs also point to a form minute order 28 1 Accordingly, the Court finds the breach of the Skye Confidentiality Agreement unsupported 2 by the evidence and not consistent with the plain language of the contract. The Court therefore 3 GRANTS Banman’s Rule 50 Motion on this claim (as to the Skye Confidentiality Agreement only) 4 and dismisses it as a matter of law.10 5 C. Skye’s Breach of Duty Claims are Supported (Counts 10 & 11) 6 As to Skye’s breach of fiduciary duty and breach of loyalty claims, Banman contests the 7 jury’s finding that he was “an officer of Skye,” and additionally as to the breach of loyalty claim, 8 that he was an officer “who participated in the management of Skye and exercised discretionary 9 authority.” Verdict Form at 17, 19. 10 i. The jury properly found that Banman owed fiduciary duties. 11 Banman first argues that a jury could not have reasonably found that that Banman was an 12 officer of Skye because Skye’s Limited Liability Company Operating Agreement did not appoint 13 him as such or assign any fiduciary duties. JMOL at 17. As an initial matter, as reflected in Jury 14 Instruction No. 48, fiduciary duties are not limited to employees who have a formal officer title 15 under Delaware law.11 ECF No. 508 at 56 (instructing that “[a]ny person who performs functions 16 usually performed by an officer of a limited liability company is considered an officer of the limited 17 liability company”); see Sci. Accessories Corp. v. Summagraphics Corp., 425 A.2d 957, 962 (1980) 18 (explaining that the “principles and limitations of agency law carry over into the field of corporate 19 employment so as to apply not only to officers and directors but also to key managerial personnel”). 20 Therefore, it is irrelevant whether or or not Skye’s LLC operating agreement or any other formal 21 document established Banman as an officer. What is relevant, however, is whether Banman 22 23 24 10 However, the Court makes no findings on the broader Employment Agreement that the jury also found liability for. Verdict Form at 13. Accordingly, that finding still stands. 25 11 Banman provides authority citing both California and Delaware law on this issue. Under California law, “[t]he law of the state or other jurisdiction under which a foreign limited liability company is formed governs” 26 its internal affairs. Cal. Corp. Code § 17708.01; see also Davis & Cox v. Summa Corp., 751 F.2d 1507, 1527 (9th Cir. 1985) (“Claims involving ‘internal affairs’ of corporations, such as the breach of fiduciary duties, are 27 subject to the laws of the state of incorporation.’). Accordingly, as it is undisputed that Skye is a Delaware LLC, the Court finds Delaware law controlling on this issue. JMOL at 17. Nevertheless, as the parties both 28 1 participated in management such that he owed fiduciary duties nonetheless. See In re NSC 2 Wholesale Holdings LLC, 637 B.R. 71, 87 (D. Del. 2022) (permitting breach of fiduciary duty claim 3 to proceed against a defendant where the complaint sufficiently showed “that [the defendant] did, in 4 fact, exert some level of control over [the LLC’s] day to day operations which may warrant 5 imposing fiduciary duties upon him”). 6 Banman further argues that there is insufficient evidence supporting a finding that Banman 7 participated in Skye’s management and exercised discretionary authority. JMOL at 19. Banman 8 points to the fact that Skye’s LLC operating agreement expressly limits management authority to its 9 sole member, Skye Biologics Holdings. Id. Again, the Court does not find the express terms of the 10 operating agreement dispositive, as Plaintiffs provided evidence from which a reasonable jury could 11 find that Banman did in fact exercise control over the company. Specifically, Plaintiffs provided 12 evidence that Banman was a Senior Vice President of Business Development, that he was the 13 “number two person in the company” who managed over 150 sales distributors, and that he had 14 “discretionary management authority” in a number of areas of the business. ECF No. 551-5 at 50:6- 15 16, 52:20-22, 67:13-16; see Beard Rsch., Inc. v. Kates, 8 A.3d 573, 602 (Del. Ch. 2010) (finding that 16 a defendant who “held the position of Executive Vice President and was second in command . . . 17 both an officer and one of the key managerial personnel of [the company] and, therefore owed that 18 company fiduciary duties”). 19 Banman also emphasizes that his employment agreement with Skye states that he agreed to 20 “commit to offering the level [of] service and dedication” as he had when he was a consultant. ECF 21 No. 540-9. Banman argues that when he was an independent business development consultant, he 22 was not exercising management authority. However, the language in the employment agreement, 23 which counsel for Banman described as “very bare bones,” can be interpreted otherwise—the “level 24 [of] service and dedication” could be interpreted as the amount of effort and quality of the work 25 expected, as opposed to meaning that Banman was to perform the same tasks as he did before. ECF 26 No. 605 at 7:5-6. And, rather than relying on the terms of this “bare bones” employment agreement, 27 the jury was justified in relying on the evidence it heard with regards to the work Banman actually 28 did as Skye’s employee and the role he played in the business overall—including managing and 1 supervising others, leading sales and business development for the company as a whole, and 2 overseeing projects.12 3 Banman cites GAB to argue that a nominal officer with no management authority is not a 4 fiduciary, which lends support to the inverse here—even if Banman did not have a formal officer 5 title, he could owe fiduciary duties because he did participate in the management of the company. 6 JMOL at 19; see GAB Bus. Servs., Inc. v. Lindsey & Newsom Claim Servs., Inc., 83 Cal. App. 4th 7 409, 420–21 (2000) (concluding that “an officer who participates in management of the corporation, 8 exercising some discretionary authority, is a fiduciary of the corporation as a matter of law”).13 As 9 the California Court of Appeal explained in Huong Que, “[t]he duty of loyalty arises not from a 10 contract but from a relationship—here, the relationship of principal and agent.” Huong Que, Inc. v. 11 Luu, 150 Cal. App. 4th 400, 410–11 (2007). “Where such a relationship arises, the agent ‘assumes a 12 fiduciary duty to act loyally for the principal’s benefit in all matters connected with the agency 13 relationship.’” Id. at 411. Banman cites no authority providing a requirement that a defendant have 14 any specific title with a company as a prerequisite to owing fiduciary duties. Rather, whatever the 15 formal title of an individual, he owes fiduciary duties if the scope of his duties makes it so. See, e.g., 16 Cal. Physicians’ Service v. Johnson, 2019 WL 1578359, *9 (Cal. App. Apr. 12, 2019) (noting that 17 while “a bare employee-employer relationship does not ordinarily create a fiduciary duty, employees 18 do owe a fiduciary duty when they accept a position of trust and confidence with their employer”) 19 (internal citations omitted). 20 21

22 12 Banman also refers to a list of specific things that he did not do or have authority to do—check-writing authority, access to bank accounts and tax returns, access to operating documents, serving on the board, or 23 signing contracts. JMOL at 19–20. However, he cites no law stating that a lack of these things precludes a 24 finding that an individual has managerial authority or can owe a fiduciary duty. 13 The Court finds the cases relied on by Banman distinguishable from the facts at hand. See Officia Imaging, 25 Inc. v. Langridge, 2018 WL 6137183, at *11 (C.D. Cal. Aug. 7, 2018) (merely alleging that the defendant was a “‘Sales Account Manager’ ‘whose primary duty was to generate business’” is not sufficient to plead that he 26 owed a fiduciary duty); Agfa Corp. v. Richard, 2018 WL 3078585, at *3 (C.D. Cal. June 1, 2018) (finding that a defendant’s position as a “regional account manager” did not “suggest the type of discretionary 27 management authority typically necessary to establish a fiduciary relationship”). Here, there is evidence from which a jury could draw facts that Banman, as someone in a fairly senior Vice President role, had discretion 28 1 The Court finds that there was sufficient evidence from which the jury could draw a 2 reasonable finding that Banman had management or discretionary authority over the company such 3 that he owed fiduciary duties, including duties to act in Skye’s best interest and not to compete with 4 it. GAB, 83 Cal. App. 4th at 421 (noting that “[w]hether a particular officer participates in 5 management is a question of fact” and expecting “that in most cases, this test will be easily met”). 6 Accordingly, Banman is not entitled to judgment as a matter of law on this issue. 7 ii. The breach of duty claims are not preempted by trade secret law. 8 Banman also argues that non-contractual civil claims are preempted by trade secret law, 9 citing K.C. Multimedia, Inc. v. Bank of Am. Tech. & Operations, Inc. 171 Cal. App. 4th 939 (2009). 10 The California Uniform Trade Secrets Act (“CUTSA”) includes a preemption provision, which 11 “implicitly prevents alternative civil remedies based on trade secret misappropriation.” Id. at 954. 12 “As reflected in case law decided under the California statute, the determination of whether a claim 13 is based on trade secret misappropriation is largely factual.” Id. This preemption does not apply to 14 contract claims or “noncontract claims that, although related to a trade secret misappropriation, are 15 independent and based on facts distinct from the facts that support the misappropriation claim.” 16 Angelica Textile Servs., Inc. v. Park, 220 Cal. App. 4th 495, 506 (2013). 17 In Angelica, the California Court of Appeals held that a breach of fiduciary duty claim was 18 not preempted by a trade secret claim, because they were “based on [the defendant’s] conduct in 19 violating the noncompetition agreement and violating his duty of loyalty.” Id. at 508 (finding that 20 this theory of liability “was independent of any trade secret claim” and therefore not preempted). 21 Citing Angelica, the Ninth Circuit reversed a lower court’s decision finding that a breach of fiduciary 22 claim was preempted by CUTSA. Integral Dev. Corp. v. Tolat, 675 Fed. Appx. 700, 704 (9th Cir. 23 2017) (“If a breach of fiduciary duty is not ‘based on the same nucleus of facts as [the] trade secret 24 misappropriation,’ CUTSA will not preempt the claim.”). The Ninth Circuit specifically noted that a 25 breach of fiduciary claim based on a breach of confidence “does not require that the confidential 26 information qualify as a ‘trade secret” and, therefore, has an independent basis and was not 27 preempted. Id. Although Banman cites to non-binding authority prior to the Ninth Circuit’s decision 28 1 in Tolat, the Court finds this case, which Banman fails to address, persuasive. JMOL Reply at 12.14 2 While facts related to the disclosure of confidential information are part of the breach of duty claims, 3 there are also distinct allegations to those claims. See Fourth Amended Complaint ¶¶ 250–267 4 (alleging that Banman had a duty to “act with the utmost good faith in the best interests of SKYE, 5 not to compete with SKYE, to protect its interests, and refrain from doing anything that would injure 6 SKYE or deprive it of profit or advantage”). For example, a jury could simply have found that 7 Banman acted against Skye’s best interests because he started a competing company while he owed 8 duties to Skye. Here, the thrust of Skye’s claims is Banman’s breach of certain duties owed to it— 9 and these claims survive regardless (and despite the failure) of its trade secret misappropriation 10 claims—so there is an independent basis for these claims. 11 Accordingly, the Court does not find preemption a basis to grant judgment as a matter of law. 12 D. The Damages are Supported by the Evidence 13 Banman argues that Plaintiffs did not present sufficient evidence of damages, taking issue 14 specifically with the opinion of Plaintiffs’ expert, Henry Kahrs. JMOL at 22.15 Banman states that 15 Khars did not apply “expert methodology” and complains that his opinions consisted of “basic 16 arithmetic.” JMOL at 23. However, the Court finds that “basic arithmetic” can be a proper way to 17 calculate damages. Id. Banman also argues that Khars’s opinions were based on the assumption “that 18 CTM could not exist at all without misappropriating confidential information.” Id. But, such an 19 assumption could reasonably have been drawn from the evidence presented at trial—namely, that 20 Banman would not have been successful at starting his own company without breaching his legal 21 22 14 The Court finds the cases cited by Banman that did not specifically deal with breach of duty claims 23 inapposite. See Artec Grp., Inc. v. Klimov, 2016 WL 8223346, at *6 (N.D. Cal. Dec. 22, 2016) (finding 24 preemption on claims for unjust enrichment, civil conspiracy, constructive trust, and unfair competition); Total Recall Tech. v. Luckey, 2016 WL 199796, at *6 (N.D. Cal. Jan. 16, 2016) (discussing preemption in the 25 context of claims for conversion, constructive fraud, unfair competition law). Moreover, to the extent that cases did deal with breach of duty claims, the Court finds that Tolat more persuasive with respect to these 26 claims. See Mattel, Inc. v. MGA Ent., Inc., 782 F. Supp. 2d 911, 988 (C.D. Cal. Jan. 5, 2011). 15 Banman previously brought a motion in limine to exclude Khars’s testimony, which the Court denied. ECF 27 No. 428 at 17 (holding that Khars has appropriate credentials and that Defendants’ arguments “go towards factual disagreement, bias, and weight, but not his actual qualifications or an absence of the basis for his 28 1 obligations to Plaintiffs. ECF No. 540-26, 61:7-16 (opining that CTM would not be a “viable 2 business” if they had not been working on a flowable product, because “[i]f all they were doing is 3 selling membranes, they would be doing a million dollars a year, and they wouldn’t be able to make 4 it over time”). This is further supported by his opinion that not just anyone could just get a business 5 up and running—while CTM may have existed prior to selling its own products, it would be 6 permissible for Kahrs to opine that it may not have been successful on the scale that it was after it 7 sold the products at issue. ECF No. 535 at 29:3-31:5. Therefore, damages could reasonably be 8 calculated by simply encompassing CTM’s total income and applying Skye’s profit margin. 9 Moreover, the Court does not find that it was improper to assume a “two-player market” of only 10 CTM and Skye,16 as there was evidence from which a jury could find that that they were the only 11 competitors in the product for a unique flowable product. ECF No. 551-10 at 31:18-32:4 (opining 12 that Skye and CTM are “outpacing their competition in terms of growth and margin, which indicates 13 [] they’re selling something that is different and unique”).17 14 Banman also notes that Kahrs did not limit his damages to Skye’s breach of duty claims, 15 which he argues should have only been tied to conduct during the period of Banman’s employment 16 of April 18, 2018 to July 2, 2018. JMOL at 23. While the Court has previously decided that the 17 claim can only be tied to conduct from this time period (ECF No. 455 at 3), Banman provides no 18 reasoning as to why damages stemming from the conduct should be so limited temporally. The jury 19

20 16 At the hearing, counsel for Banman argued against this assumption by stating that HRT’s product “is sold 21 to Stryker, and Stryker sells it,” arguing that this is evidence there are at least three companies in the market selling HRT’s unique product. ECF No. 605 at 21:15-20. But, a company that HRT sells to would logically 22 seem to be part of HRT’s market for purposes of Kahr’s analysis here, and regardless was accounted for by him. ECF No. 535 at 58:3-59:1. 23 17 Although not explicitly argued in his moving papers, Banman appears to take issue with Khars’s lack of 24 apportionment of the damages as to different confidential information and different claims, citing O2 Micro Int’l Ltd. v. Monolithic Power Sys., Inc., 399 F. Supp. 2d 1064, 1076 (N.D. Cal. 2005). JMOL at 22; JMOL 25 Reply at 10. But, as the Court previously ruled, apportionment is not required. See SPS Techs., LLC v. Briles Aerospace, Inc., 2021 WL 4913509, at *3 (C.D. Cal. Sept. 8, 2021) (noting that “California authority does not 26 require an apportionment of damages”). And, in this case specifically, given that a jury could find that CTM would not successfully exist without Banman’s misconduct, such apportionment is unnecessary. Id. (noting 27 that O2 Micro does not apply where “there is no damages claim for the value of the trade secrets themselves”). Accordingly, the discussion in the concurrence in BladeRoom Grp. Ltd. v. Emerson Elec. Co., 28 1 found that Banman breached his fiduciary duties and the duty of loyalty. Banman cites no authority 2 for the propostion that the damages sustained—which may not necessarily be the same as when the 3 conduct occurred—should be temporally limited. It is a reasonable inference that the conduct of 4 creating a competing company causes damages that can be ongoing, throughout the competing 5 company’s existence. Accordingly, the Court finds the damages properly supported. 6 RULE 59 MOTION (MOTION FOR NEW TRIAL) [ECF NO. 544] 7 I. Applicable Law 8 “The court may, on motion, grant a new trial on all or some of the issues...for any reason 9 for which a new trial has heretofore been granted in an action at law in federal court.” Fed. R. Civ. P. 10 59(a)(1). Rule 59 does not specify the grounds upon which a new trial may be granted, but the Ninth 11 Circuit recognizes that courts are bound by historically recognized grounds. For example, a new trial 12 may be granted “if the verdict is contrary to the clear weight of the evidence, is based upon false or 13 perjurious evidence, or to prevent a miscarriage of justice.” Molski v. M.J. Cable, Inc., 481 F.3d 724, 14 729 (9th Cir. 2007) (quoting Passantino v. Johnson & Johnson Consumer Prods., 212 F.3d 493, 510 15 n.15 (9th Cir. 2000)). Courts “enjoy[] considerable discretion” in deciding a new trial motion. 16 Jorgensen v. Cassiday, 320 F.3d 906, 918 (9th Cir. 2003) (internal quotation marks omitted). 17 “[A] jury’s award of damages is entitled to great deference, and should be upheld unless the 18 amount is clearly not supported by the evidence or only based on speculation or guesswork.” In re 19 First All. Mortg. Co., 471 F.3d 977, 1001 (9th Cir. 2006) (internal quotation marks omitted); accord 20 Chalmers v. City of Los Angeles, 762 F.2d 753, 760 (9th Cir. 1985) (requiring jury’s award to be 21 upheld unless “grossly excessive or monstrous or shocking to the conscience” (internal quotation 22 marks omitted)). Awards must be upheld “whenever possible, and all presumptions are in favor of 23 the judgment.” DSPT Int’l, Inc. v. Nahum, 624 F.3d 1213, 1224 (9th Cir. 2010) (internal quotation 24 marks omitted). 25 For punitive damages specifically, a plaintiff seeking a punitive damages award bears the 26 burden of proving a defendant’s financial condition. Adams v. Murakami, 813 P.2d 1348, 1358 27 (1991). This is because evidence of the defendant’s financial condition is crucial to the jury—and a 28 reviewing court—in determining “whether the amount of the award is appropriate and, in particular, 1 whether it is excessive in light of the central goal of deterrence.” Id. As the California Supreme 2 Court has held, “[f]undamental fairness must be the lodestar for our analysis. . . These bedrock 3 concerns—policy and fairness—support placing the burden on a plaintiff to prove a defendant’s 4 financial condition.” Id. at 1357; see also Kaffaga 938 F.3d 1006, 1018 (9th Cir. 2019) (“It is the 5 plaintiff’s burden to place into the record ‘meaningful evidence of the defendant’s financial 6 condition to support a defendant’s ability to pay.’” (citing Adams)). And, the defendant’s financial 7 condition means net figures, not gross, so the plaintiff must present evidence of assets, income, 8 liabilities, and expenses for a punitive damages award to survive. Id. at 1018. 9 Once that evidence has been presented, “there are no rigid benchmarks that a punitive 10 damages award may not surpass,” but the award “must be based upon the facts and circumstances of 11 the defendant’s conduct at the harm to the plaintiff.” State Farm Mut. Auto. Ins. Co. v. Campbell, 12 538 U.S. 408, 425 (2003). To determine whether punitive damages are excessive, courts consider 13 three guideposts: “(1)the degree of reprehensibility, (2)the disparity between the harm suffered and 14 the punitive damages award, and (3)the difference between this remedy and the civil penalties 15 authorized or imposed in comparable cases.” Bains LLC v. ARCO Prods. Co., 405 F.3d 764, 775 16 (9th Cir. 2005) (citing BMW of N. Am., Inc. v. Gore, 517 U.S. 559, 574–75 (1996)). The first 17 guidepost is “[p]erhaps the most important.” Gore, 517 U.S. at 575. 18 II. Discussion 19 Banman also moves under Rule 59 for a new trial, to strike or limit damages, or for 20 remittitur, arguing that (1) there were prejudicial legal errors; (2) the verdict is unsupported by the 21 evidence; (3) the actual damages are unsupported, excessive, and contrary to the evidence; (4) and 22 the punitive damages are excessive and in violation of state law. For the reasons discussed below, 23 the Court finds that there were no prejudicial legal errors, the verdict is supported by the evidence, 24 and the actual damages are supported. However, the Court finds that the punitive damages are not 25 supported. Accordingly, the Court vacates the award for punitive damages as to Counts 10 and 11. 26 A. No Legal Errors Justify the Granting of a New Trial 27 i. Plaintiffs’ expert testimony was properly admitted. 28 1 Banman first challenges the admissibility of testimony from Plaintiffs’ experts, Daniel Cisco 2 and Henry Khars. As to Cislo, Banman challenges his qualifications through similar arguments 3 raised in a prior motion in limine. ECF No. 338. The Court previously limited Cislo’s testimony “as 4 to noninfringement or invalidity, as he is not qualified to so testify,” but specifically permitted 5 testimony to distinguish the patents at issue in this case. ECF No. 428 at 22. This is what Cislo did at 6 trial. Banman takes issue with Cislo’s testimony that he did not “find in any one patent the critical 7 features that are found in some of the Plaintiffs’ provisional patents and [he] did not find critical 8 methodology that is described in some of their standard operating procedures.” ECF No. 544-24 at 9 156:14-20. While Cislo may not have the qualification to independently determine what the “critical 10 features” or “methodology” were, a reasonable interpretation is that Cislo was using the word 11 “critical” to mean the features and methodology that he has been instructed are at issue in this case. 12 ECF No. 554-2 at 155:1-8 (testifying that his work is to “understand from [] the perspective [of a 13 person skilled in the art] what is important and what processes are important” and that he works with 14 clients who are “skilled in the art to figure out what is—what are the critical features”).18 Having 15 been told what the critical features are of HRT’s manufacturing process, Cislo was properly 16 qualified to testify as to whether those features were apparent in other patents. 17 Banman presents a hypothetical situation where HRT’s process was disclosed on a webpage. 18 MNT Reply at 2. Banman asserts that in such a scenario, Plaintiffs could not rely on a webpage 19 designer to testify as to whether the webpage disclosed the process, and “would need to” rely on an 20 expert in the relevant art. Id. However, the Court does not find that to be the case. If such disclosure 21 was obvious, no expert would be needed at all. A more apt hypothetical would be if HRT’s process 22 was disclosed in code on the website—then, it would be undoubtedly appropriate for Plaintiffs to 23 have a webpage designer interpret and translate the code to testify as to whether the processes they 24 have been told to look for exist within that code. The Court finds this to be in the ambit of what 25 26 27 18 See ECF No. 309-1 at 6–7 (stating in his expert report that Cislo talked to Plaintiffs’ biologics expert, John 28 1 Cislo did, albeit in the context of patents.19 Therefore, the Court finds Cislo’s testimony 2 permissible.20 3 Banman makes the same arguments as to the testimony of Khars as in his Rule 50 Motion. 4 For the reasons discussed in its prior analysis, the Court does not find that Khars’s testimony was 5 unreliable. See JMOL Order Section II.D, supra. 6 ii. Jury Instruction 48 was not wrong as a matter of law. 7 As discussed with Banman’s Rule 50 motion, the Court finds that Jury Instruction 48, 8 instructing that “[a]ny person who performs functions usually performed by an officer of a limited 9 liability company is considered an officer of the limited liability company,” was not a misstatement 10 of the law. See JMOL Order Section II.C.i, supra. While it may have been clearer to define fiduciary 11 duties as owed by one who exercises discretionary authority over the management of the company, 12 regardless of the formal title of officer, the Court finds that this instruction would not lead the jury to 13 a finding contrary to the law. See Clem v. Lomeli, 566 F.3d 1177, 1181 (9th Cir. 2009) (explaining 14 that reversal is not warranted where the error in the jury instruction is harmless).21 Here, taken 15 together with the remainder of Instruction 48, the contested part of the instruction is not wrong. The 16 instruction defines an officer as one who “participates in the management of a company and 17

18 19 At the hearing, counsel for Banman argued that the patents were in “English prose,” which do not require 19 translation. ECF No. 605 at 17:8-9. On direct, Cislo testified specifically as to one patent (ECF No. 544-16) which Banman puts at issue (MNT at 6) and explained why he did not believe it to disclose Plaintiffs’ 20 confidential processing and formulas. See ECF No. 535 at 12:9-16. Banman could have cross-examined Cislo on his reasoning using the plain language of the patent, and attempted to use such testimony to demonstrate 21 why Cislo’s testimony was beyond the scope of his expertise (rather, Cislo was cross-examined on another patent and supported his interpretation with the plain language reading of that patent). See ECF No. 536 at 22 11:5-12:4. However, as there was no such cross-examination, Banman has failed to identify any specific testimony about the patents beyond Cislo’s general opinion that is impermissible. 23 20 Even if Cisco’s testimony was improperly admitted, the Court finds that it would not have been prejudicial. 24 See Ruvalcaba v. City of Los Angeles, 64 F.3d 1323, 1328 (9th Cir. 1995) (“A new trial is only warranted when an erroneous evidentiary ruling ‘substantially prejudiced’ a party.”). As explained in the Court’s 25 discussion on the Rule 50 Motion, the existence of some parts of the process in a public patent would not necessarily preclude it from being confidential information. See JMOL Order Section II.A.i, supra. 26 21 Although not contested by Banman, the Court finds that Instructions No. 49 and 50, which include a requirement that Plaintiffs prove that Banman is an officer as an element of the breach of fiduciary duty and 27 breach of loyalty claims, may therefore be in error. ECF No. 508 at 57–58. However, any errors are not prejudicial—as the jury found all the other required elements of these claims, the negation of an additional 28 1 exercises discretionary authority,” and that an officer owes fiduciary duties. ECF No. 508 at 56. 2 Therefore, the contested line implies that any person who participates in management and exercises 3 discretionary authority owes fiduciary duties, which the Court finds to be the correct interpretation 4 of the law. While Banman focuses on whether he could be found an officer without some sort of 5 formal appointment, regardless of this title, he could be found to owe fiduciary duties if he 6 participated in management and exercised discretionary authority under applicable law. See Sci. 7 Accessories Corp. v. Summagraphics Corp., 425 A.2d 957, 962 (1980) (explaining that an agent 8 “can make arrangements or plans to go into competition with his principal . . . provided no unfair 9 acts are committed or injury done his principal” and that these principles “apply not only to officers 10 and directors but also to key managerial personnel”); GAB Business Services v. Lindsey & Newsom 11 Claim Services, 83 Cal. App. 4th 409, 420 (2004) (explaining that “something more than bare title” 12 is required to determine fiduciary status). As any error in the instruction is harmless, the Court does 13 not find this warrants a new trial. 14 B. The Verdict is Supported by the Evidence 15 Banman argues that the liability verdict was against the clear weight of the evidence, relying 16 on the arguments made in his Rule 50 motion. The Court addresses only the new arguments made as 17 to the Rule 59 motion, which solely concern the breach of the HRT contract (Count 4). 18 As to breach of the HRT contract, Banman relies on the testimony of his expert, Dr. Rouzbeh 19 Taghizadeh, to bolster his argument that HRT’s manufacturing process was commonly known and 20 was not used by Banman because Alamo’s manufacturing process was different than HRT’s. MNT 21 at 12. However, the Court does not find Dr. Taghizdeh’s testimony to move the needle on these 22 arguments. At most, Dr. Taghizdeh confirmed that the basic manufacturing steps may be available 23 publically, but not the specific steps alleged to be confidential in this case to make the specific 24 product at issue. ECF No. 536 at 30:4-6, 33:5-7, 39:24-40:4. Further, despite any differences in 25 Alamo and HRT’s processes, the evidence plainly shows that Banman specifically instructed Alamo 26 to replicate key parts of HRT’s processes, including the maintenance of the stromal layer and the use 27 of the 75:1 ratio. ECF No. 553-3 at 31:22-32:2, 32:17-21. 28 1 Accordingly, the Court finds that the verdict as to Count 4 is not against the weight of the 2 evidence. As Banman makes no new arguments as to the remaining counts, the Court cites its 3 analysis as to the Rule 50 motion and makes no new findings here. 4 C. The Actual Damages Award is Not Inconsistent 5 In arguing that the damages are unsupported, Banman again takes issue with a lack of 6 apportionment by Khars. MNT at 15. As previously explained, the Court does not find this to lead to 7 an unsupported damages award. Banman also argues that it cannot be determined where the jury got 8 the figure of $7,298,949 from, which is the same damages the jury gave to every claim. However, 9 “the fact that the damages award does not precisely correspond to any method of calculation 10 proposed by either party is not a significant cause for concern.” Cardinal v. Lupo, 2020 WL 11 1694355, at *3 (N.D. Cal. Apr. 7, 2020). Rather, “while the fact of damages must be clearly shown, 12 the amount need not be proved with the same degree of certainty,” so long as a “reasonable 13 approximation” is made. Robi v. Five Platters, Inc., 918 F.2d 1439, 1443 (9th Cir. 1990). Therefore, 14 the Court analyzes whether the damages awarded by the jury finds any support in the evidence 15 presented by the parties. 16 Plaintiffs primarily rely on the projections prepared by Khars that was not admitted into 17 evidence, but was shown to the jury as a demonstrative, to support the amount of the award. ECF 18 No. 535 at 36:22-37:6; ECF No. 554-9 (“Lost Profit Chart”). Khars testified that the “total past loss 19 for Skye is $30,816,474,” and $4,102,291 for HRT. ECF No. 535 at 37:13-18. In getting to this 20 number, he explained that he took the actual revenue for CTM, multiplied by Skye’s net margin, 21 which is “roughly 57 percent.” Id. 38:1-8. For future profits, Khars “projected CTM’s revenue into 22 the future,” settling on an increase of 30%, then 20%, 15%, and 10%, then after eight years, only 23 having increases calculated by inflation. Id. at 39:6-40:3. While Banman argues that the Lost Proft 24 Chart is not admitted evidence, Banman does not object to the underlying financial information from 25 CTM, Skye, or HRT that Khars relies on in calculating these numbers. Therefore, a jury could rely 26 on the projections set forth in the Lost Profits Chart, if the rationale for his calculations is supported. 27 Here, the Court finds that the compensatory damages awarded find some grounding in 28 Khars’s calculations. As to HRT, the jury awarded $7,298,949 only for its sole breach of contract 1 claim. Khars calculated HRT’s past lost profits to be $4,102,291—Banman argues that this clearly 2 signifies an excessive award because the award is almost twice this calculation. MNT at 15. 3 However, Banman fails to explain why lost profits should be limited, as a matter of law, to past lost 4 profits. Rather, considering the total past and future lost profits calculated by Khars to be 5 $16,617,202 to HRT, the jury’s award of $7,298,949 is not excessive. Lost Profit Chart. Khars 6 calculated Skye’s past losses to be $30,816,474 alone, and the cumulative amount awarded to Skye 7 for compensatory damages—$29,195,796—is less than this, also not signifying an excessive award. 8 Id. Again, Banman has not justified a strict temporal limitation on the damages stemming from 9 conduct that occurred within his employment period. 10 The Court next turns to the question of whether the jury failed to separately determine 11 damages for each claim as required. Banman confidently asserts that it did, but without any support. 12 As a preliminary matter, Banman cannot rely on the structure of the verdict form itself in support of 13 this contention since Banman requested this verdict form and so any alleged failure to require a 14 separate damages determination would be invited error. Next, the simple fact that neither the parties 15 nor the Court can reverse-engineer the number also does not demonstrate that the jury failed to 16 separately determine damages or that there was no support for its verdict—particlarly since, as noted 17 above, the number is less than the past lost profits alone calculated by Khars for Plaintiffs ($34 18 million). Lost Profit Chart. But most importantly, the fact that the jury assigned identical numbers to 19 different claims does not demonstrate that the jury failed to separately determine damages. First, we 20 presume that the jury follows the Court’s instructions, CSX Transp., Inc. v. Hensley, 556 U.S. 838, 21 841 (2009), and the Court’s instructions were very clear on this—“To decide the amount of damages 22 for lost profits, you must determine the gross, or total, amount HRT and/or Skye would have 23 received if the contract had been performed . . .” ECF No. 508 at 51. And second, to aggregate and 24 divide would not be contrary to the jury instructions or to governing law. For example, in torts cases, 25 where there are multiple defendants at fault, “the sums representing the damages are added together, 26 and the amount is equally divided between the parties.” The Atlas, 93 U.S. 302, 313 (1876). 27 As the Court has already dismissed Count 5 as to the Skye Employee Confidentiality 28 Agreement contract, one duplication that Banman contests is a non-issue at this stage. Banman also 1 argues that the two breach of duty awards are duplicative of the damages stemming from the 2 remaining breach of the Skye Employment Agreement contract under Count 5. MNT at 18. 3 However, presuming that the jury properly followed the Court’s instructions and that aggregating 4 damages is not improper, there is no evidence that the jury duplicated any award. For example, it 5 seems reasonable for the jury to come to a total award and divide it evenly among the claims. This 6 may even have been the most logical way to calculate the damages—assuming that Skye suffered 7 the same harm across all of Skye’s claims, the jury may not have been able to determine how much 8 of the harm was attributable to each claim and therefore divided it evenly. This would not be the 9 same as finding a total $7,298,949 of damages and then duplicating it across each claim, and given 10 the lack of evidence that the jury did this, the Court must give deference to the jury’s award.22 11 Accordingly, the Court finds that the jury’s actual damages award supported by the evidence. 12 D. The Punitive Damages are Insufficiently Supported by Evidence of Banman’s 13 Financial Condition 14 The Court finds that there was insufficient evidence of Banman’s financial condition—either 15 his net worth or his ability to pay—to support a punitive damages award. See Kaffaga v. Estate of 16 Steinbeck, 938 F.3d 1006, 1018 (9th Cir. 2019) (“The record [] must contain sufficient evidence of [a 17 defendant’s] assets, income, and liabilities and expenses for the punitive damages award to stand.”); 18 Adams v. Murakami, 813 P.2d 1348, 1350 (1991) (noting that “absent financial evidence, a jury will 19 be encouraged (indeed, required) to speculate as to a defendant’s net worth in seeking to return a 20 verdict that will appropriately punish the defendant”). In Kaffaga, the Ninth Circuit vacated a 21 punitive award noting that while there was “some evidence” of the defendant’s financial condition, 22 it was “unable to come to even a reasonable approximation” of the defendant’s net worth. Kaffaga, 23 938 F.3d at 1019. Even assuming Skye is correct that a net worth calculation is not required, even an 24 ability to pay determination would necessarily require some consideration of Banman’s liabilities. 25

26 22 Although the granting of $7,298,949 on all the claims, both as to Skye or HRT, may at first seem like 27 evidence of improper duplication, it finds support in the evidence when aggregated. The jury awarded HRT $7,298,949 only, while it awarded Skye $7,298,949 across multiple claims, totaling over $29 million, which 28 1 But Plaintiffs appear to concede that there was no evidence, or attempt to introduce evidence of, 2 Banman’s liabilities, instead arguing that such evidence is not required. MNT Opp. at 24.23 3 Although Skye points to Banman’s admittedly evasive (or at least puzzling) answers with 4 respect to his personal income, the fact remains that he was not asked about his liabilities even 5 though it appears that it was a topic of discovery. ECF No. 567-1 (deposition testimony discussing 6 Banman’s financial condition, including a $1.3 million mortgage). Skye cites Green v. Laibco, LLC, 7 where the court found that evidence of the defendant’s net worth was lacking but still sufficient for 8 an assessment of defendant’s financial condition, because the evidence shown was of profit (not just 9 income), and there was testimony that the defendant was “in the black” (that its assets were greater 10 than its liabilities). 192 Cal. App. 4th 441, 453 (2011). Moreover, to the extent there was any lack of 11 evidence of net worth, the court in Green found that it was because the defendant stonewalled in 12 discovery. Id. at 452. Here, because there was apparently compliance with discovery on liabilities, 13 Banman’s evasive answers do not constitute the type of “stonewalling” that would permit the Court 14 to uphold a punitive damages award regardless of its relationship to net worth or ability to pay. 15 Having presented no such evidence, the Court has no basis upon which to determine that the 16 jury’s punitive damages award is justified by its relationship to Banman’s financial condition. 17 Accordingly, the Court finds that there was insufficient evidence of Banman’s financial condition 18 presented to sustain the punitive damages award.24 Nevertheless, for the first time at the hearing, 19 counsel for Skye raised the argument of what remedy is proper under a Rule 59 motion. In 20 particular, Skye argued that this Court does not have the power to vacate punitive damages, but may 21 only grant a new trial or remittitur. Accordingly, the Court will allow the parties to further brief the 22

23 23 Plaintiffs cite to Rufo v. Simpson for the proposition that all that is required is evidence of a defendant’s 24 ability to pay. 86 Cal. App. 4th 573, 621 (2001). But, a defendant’s ability to pay necessarily requires a showing of his liabilities, which Rufo supports. Id. (citing Kenly v. Ukegawa, 16 Cal. App. 4th 49, 57 (1993) 25 (“some evidence regarding liabilities must be offered”) and Robert L. Cloud & Assocs., Inc. v. Mikesell, 69 Cal. App. 4th 1141, 1152 (1999) (“income standing alone or wrongful profit standing alone is not meaningful 26 evidence”)); see also Kafaga, 938 F.3d at 1018 (“The rule established by lower California courts is that only net, not gross, figures are relevant.”). 27 24 The Court therefore does not reach the analysis of whether the amount of punitive damages meets the guideposts set forth in Bains LLC v. ARCO Prods. Co., 405 F.3d 764, 775 (9th Cir. 2005) or is 28 | | issue of what remedy is proper given the Court’s finding on the insufficiency of evidence on the 2 | punitive damages award. 3 CONCLUSION 4 For the foregoing reasons, the Court hereby ORDERS as follows: 5 1. Defendant’s Rule 50 Motion for Judgment as a Matter of Law (ECF No. 540) is GRANTED 6 IN PART; 7 a. Skye’s breach of contract claim (Count 5) as to the Skye Orthobiologics LLC 8 Employee Confidentiality Agreement only is DISMISSED; 9 2. Defendant’s Rule 59 Motion for a New Trial (ECF No. 544) is GRANTED IN PART: 10 a. The parties are ORDERED to further brief the issue of what remedy 1s appropriate 11 with regards to the punitive damages award; 12 b. A response from Skye will be due no later than May 3, 2024; 13 c. A response from Banman will be due no later than May 10, 2024; 14 d. Any reply from Skye will be due no later than May 17, 2024. 15 16 IT IS SO ORDERED. 17 Uf 18 | Dated: April 17, 2024 19 MAAME EWUSI-MENSAH FRIMPONG 20 United States District Judge 21 22 23 24 25 26 27 28